Rasna Therapeutics, Inc. (RASP) Starts Presentation at the 8th Annual LD Micro Invitational
Rasna Therapeutics, Inc. (OTCQX: RASP) is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal genetic and epigenetic modifications are recognized to play an important role in the pathogenesis of acute myeloid leukemia (“AML”). Rasna has a balanced portfolio targeting NPM1-mutated AML through direct and indirect disease-modifying approaches. The company is also exploiting inhibition of lysine specific demethylase-1 (“LSD1”), an enzyme involved in epigenetic control, as a promising and novel approach against AML. Rasna is entering preclinical development with a novel class of potent and selective reversible LSD1 regulators that have…
